Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC.

Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma / E. Zanardi, E. Verzoni, P. Grassi, A. Necchi, P. Giannatempo, D. Raggi, F. De Braud, G. Procopio. - In: THERAPEUTIC ADVANCES IN UROLOGY. - ISSN 1756-2880. - 7:3(2015 Jun), pp. 152-161.

Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma

E. Verzoni
Secondo
;
A. Necchi;P. Giannatempo;D. Raggi;F. De Braud
Penultimo
;
2015-06

Abstract

Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC.
mTOR inhibitors; renal cell carcinoma; targeted therapies; temsirolimus; urology
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
10.1177_1756287215574457.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/426847
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact